All In Biotech

Drug Trial Radar · NCT02558296

Bexagliflozin Efficacy and Safety Trial

A Double Blind Placebo Controlled Study to Evaluate the Effects of Bexagliflozin on Hemoglobin A1c in Patients With Type 2 Diabetes and Increased Risk of Cardiovascular Adverse Events

Last checked: Nov 20, 2026Latest source record: Jul 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,700 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,700

Actual

Start

Oct 2015

Primary completion

Aug 2018

Study completion Oct 23, 2019

Sponsor

Lead sponsor
TheracosIndustry
Sponsor type
Industry
First posted
Sep 23, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM) and increased risk of cardiovascular adverse events. The data from this study will be combined with the data from other bexagliflozin studies in a meta-analysis of CV safety outcomes.

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • BexagliflozinDrug

    20 mg, tablet

  • PlaceboDrug

    20 mg tablet to match active comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1c From Baseline to Week 24Time frame: 24 weeks

Locations

157 sites in 10 countries. Site status is shown where the registry gives one.

  • Research Site 1090

    Gilbert, Arizona

  • Research Site 1041

    Little Rock, Arkansas

  • Research Site 1073

    Azusa, California

  • Research Site 1076

    Concord, California

  • Research Site 1078

    Fresno, California

  • Research Site 1089

    Harbor City, California

  • Research Site 1058

    Lincoln, California

  • Research Site 1051

    Los Angeles, California

  • Research Site 1004

    Los Angeles, California

  • Research Site 1068

    Montclair, California

  • Research Site 1077

    Orange, California

  • Research Site 1218

    Denver, Colorado

  • Research Site 1092

    Golden, Colorado

  • Research Site 1216

    Norwalk, Connecticut

  • Research Site 1083

    Newark, Delaware

  • Research Site 1057

    Boca Raton, Florida

  • Research Site 1059

    Brooksville, Florida

  • Research Site 1050

    Panama City, Florida

  • Research Site 1099

    Port Charlotte, Florida

  • Research Site 1066

    Tampa, Florida

  • Research Site 1072

    Augusta, Georgia

  • Research Site 1082

    Pocatello, Idaho

  • Research Site 1258

    Champaign, Illinois

  • Research Site 1043

    Anderson, Indiana

  • Research Site 1071

    Avon, Indiana

  • Research Site 1086

    Des Moines, Iowa

  • Research Site 1224

    Covington, Kentucky

  • Research Site 1228

    Annapolis, Maryland

  • Research Site 1221

    Baltimore, Maryland

  • Research Site 1079

    Hyattsville, Maryland

  • Research Site 1223

    Midland, Michigan

  • Research Site 1217

    Petoskey, Michigan

  • Research Site 1254

    Ypsilanti, Michigan

  • Research Site 1054

    St Louis, Missouri

  • Research Site 1060

    St Louis, Missouri

  • Research Site 1252

    Kalispell, Montana

  • Research Site 1052

    Omaha, Nebraska

  • Research Site 1263

    Omaha, Nebraska

  • Research Site 1080

    Las Vegas, Nevada

  • Research Site 1219

    Somerset, New Jersey

Showing 40 of 157 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.